Investment Banking Analyst
CurrentBiotech M&A and Strategic Advisory• Up to $1.1bn sale of Jnana Therapeutics to Otsuka Pharmaceutical (closed Sep. 2024)• $924mm sale of Revance Therapeutics to Crown Labs (annc. Aug. 2024)• $3.2bn sale of Morphic Therapeutic to Eli Lilly (closed Aug. 2024)• Up to $1.05bn sale of Amolyt Pharma to AstraZeneca (closed July 2024)• $4.9bn sale of Alpine Immune Sciences to Vertex Pharmaceuticals (closed May 2024) • Up to $1.1bn sale of Icosavax to AstraZeneca (closed Feb. 2024)